Literature DB >> 16926401

Attenuated Francisella novicida transposon mutants protect mice against wild-type challenge.

Rebecca Tempel1, Xin-He Lai, Lidia Crosa, Briana Kozlowicz, Fred Heffron.   

Abstract

Francisella tularensis is the bacterial pathogen that causes tularemia in humans and a number of animals. To date, there is no approved vaccine for this widespread and life-threatening disease. The goal of this study was to identify F. tularensis mutants that can be used in the development of a live attenuated vaccine. We screened F. novicida transposon mutants to identify mutants that exhibited reduced growth in mouse macrophages, as these cells are the preferred host cells of Francisella and an essential component of the innate immune system. This approach yielded 16 F. novicida mutants that were 100-fold more attenuated for virulence in a mouse model than the wild-type parental strain. These mutants were then tested to determine their abilities to protect mice against challenge with high doses of wild-type bacteria. Five of the 16 attenuated mutants (with mutations corresponding to dsbB, FTT0742, pdpB, fumA, and carB in the F. tularensis SCHU S4 strain) provided mice with protection against challenge with high doses (>8 x 10(5) CFU) of wild-type F. novicida. We believe that these findings will be of use in the design of a vaccine against tularemia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16926401      PMCID: PMC1594869          DOI: 10.1128/IAI.00598-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  46 in total

1.  Construction of a reporter plasmid for screening in vivo promoter activity in Francisella tularensis.

Authors:  K Kuoppa; A Forsberg; A Norqvist
Journal:  FEMS Microbiol Lett       Date:  2001-11-27       Impact factor: 2.742

2.  Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen.

Authors:  J Wayne Conlan; Hua Shen; Ann Webb; Malcolm B Perry
Journal:  Vaccine       Date:  2002-10-04       Impact factor: 3.641

3.  Efficacy of the live attenuated Francisella tularensis vaccine (LVS) in a murine model of disease.

Authors:  Michael Green; Glyn Choules; Debbie Rogers; Richard W Titball
Journal:  Vaccine       Date:  2005-04-08       Impact factor: 3.641

4.  Sequencing of the Francisella tularensis strain Schu 4 genome reveals the shikimate and purine metabolic pathways, targets for the construction of a rationally attenuated auxotrophic vaccine.

Authors:  J Karlsson; R G Prior; K Williams; L Lindler; K A Brown; N Chatwell; K Hjalmarsson; N Loman; K A Mack; M Pallen; M Popek; G Sandström; A Sjöstedt; T Svensson; I Tamas; S G Andersson; B W Wren; P C Oyston; R W Titball
Journal:  Microb Comp Genomics       Date:  2000

Review 5.  Vaccination strategies for Francisella tularensis.

Authors:  Karen E Isherwood; Richard W Titball; D Huw Davies; Phillip L Felgner; W John W Morrow
Journal:  Adv Drug Deliv Rev       Date:  2005-06-17       Impact factor: 15.470

6.  Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism.

Authors:  J Wayne Conlan; Hua Shen; Rhonda Kuolee; Xigeng Zhao; Wangxue Chen
Journal:  Vaccine       Date:  2005-03-31       Impact factor: 3.641

7.  Francisella novicida LPS has greater immunobiological activity in mice than F. tularensis LPS, and contributes to F. novicida murine pathogenesis.

Authors:  Tara L Kieffer; Siobhan Cowley; Francis E Nano; Karen L Elkins
Journal:  Microbes Infect       Date:  2003-04       Impact factor: 2.700

8.  A Francisella tularensis pathogenicity island required for intramacrophage growth.

Authors:  Francis E Nano; Na Zhang; Siobhán C Cowley; Karl E Klose; Karen K M Cheung; Michael J Roberts; Jagjit S Ludu; Gregg W Letendre; Anda I Meierovics; Gwen Stephens; Karen L Elkins
Journal:  J Bacteriol       Date:  2004-10       Impact factor: 3.490

9.  Role of lipopolysaccharide and a major outer membrane protein from Francisella tularensis in the induction of immunity against tularemia.

Authors:  M Fulop; R Manchee; R Titball
Journal:  Vaccine       Date:  1995-09       Impact factor: 3.641

Review 10.  Protein disulfide bond formation in prokaryotes.

Authors:  Hiroshi Kadokura; Federico Katzen; Jon Beckwith
Journal:  Annu Rev Biochem       Date:  2003-01-09       Impact factor: 23.643

View more
  60 in total

1.  Francisella tularensis Schu S4 O-antigen and capsule biosynthesis gene mutants induce early cell death in human macrophages.

Authors:  Stephen R Lindemann; Kaitian Peng; Matthew E Long; Jason R Hunt; Michael A Apicella; Denise M Monack; Lee-Ann H Allen; Bradley D Jones
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

2.  Directed screen of Francisella novicida virulence determinants using Drosophila melanogaster.

Authors:  Monika K Ahlund; Patrik Rydén; Anders Sjöstedt; Svenja Stöven
Journal:  Infect Immun       Date:  2010-05-17       Impact factor: 3.441

3.  The Protease Locus of Francisella tularensis LVS Is Required for Stress Tolerance and Infection in the Mammalian Host.

Authors:  Lihong He; Manoj Kumar Mohan Nair; Yuling Chen; Xue Liu; Mengyun Zhang; Karsten R O Hazlett; Haiteng Deng; Jing-Ren Zhang
Journal:  Infect Immun       Date:  2016-04-22       Impact factor: 3.441

4.  Francisella tularensis subsp. tularensis Schu S4 disulfide bond formation protein B, but not an RND-type efflux pump, is required for virulence.

Authors:  Aiping Qin; David W Scott; Barbara J Mann
Journal:  Infect Immun       Date:  2008-05-05       Impact factor: 3.441

5.  Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization.

Authors:  J Wayne Conlan; Hua Shen; Igor Golovliov; Carl Zingmark; Petra C F Oyston; Wangxue Chen; Robert V House; Anders Sjöstedt
Journal:  Vaccine       Date:  2009-12-16       Impact factor: 3.641

Review 6.  Tularemia vaccines.

Authors:  Daniela Putzova; Iva Senitkova; Jiri Stulik
Journal:  Folia Microbiol (Praha)       Date:  2016-05-19       Impact factor: 2.099

7.  Pivotal role of the Francisella tularensis heat-shock sigma factor RpoH.

Authors:  Nathalie Grall; Jonathan Livny; Matthew Waldor; Monique Barel; Alain Charbit; Karin L Meibom
Journal:  Microbiology (Reading)       Date:  2009-05-14       Impact factor: 2.777

8.  Identification of an essential Francisella tularensis subsp. tularensis virulence factor.

Authors:  Aiping Qin; David W Scott; Jennifer A Thompson; Barbara J Mann
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

9.  Infection with Francisella tularensis LVS clpB leads to an altered yet protective immune response.

Authors:  Lydia M Barrigan; Shraddha Tuladhar; Jason C Brunton; Matthew D Woolard; Ching-ju Chen; Divey Saini; Richard Frothingham; Gregory D Sempowski; Thomas H Kawula; Jeffrey A Frelinger
Journal:  Infect Immun       Date:  2013-03-25       Impact factor: 3.441

10.  Identification of trkH, encoding a potassium uptake protein required for Francisella tularensis systemic dissemination in mice.

Authors:  Khaled Alkhuder; Karin L Meibom; Iharilalao Dubail; Marion Dupuis; Alain Charbit
Journal:  PLoS One       Date:  2010-01-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.